11.01.2015 Views

Taking Control: Emerging Issues in Pain ... - Pharmacy Times

Taking Control: Emerging Issues in Pain ... - Pharmacy Times

Taking Control: Emerging Issues in Pain ... - Pharmacy Times

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Barriers to Pa<strong>in</strong> Management<br />

• Hear<strong>in</strong>g patients, but not<br />

listen<strong>in</strong>g<br />

• Low priority given to pa<strong>in</strong><br />

treatment<br />

• Lack of consistent<br />

documentation<br />

• Abuse concerns by<br />

cl<strong>in</strong>icians, patients, family<br />

• Enforcement: laws and<br />

regulation constra<strong>in</strong>ts<br />

• Judgment issues<br />

• Mean<strong>in</strong>g of pa<strong>in</strong> to patient<br />

• Need to follow up<br />

• F<strong>in</strong>ancial implications<br />

• Fear of not be<strong>in</strong>g viewed as<br />

“good” patient<br />

• Hesitation to seek medical<br />

attention<br />

• Dangers: adverse effects,<br />

management, awareness<br />

Differences Between Acute<br />

and Chronic Pa<strong>in</strong><br />

Acute (Nociceptive) Pa<strong>in</strong><br />

Has biologic function 1<br />

Chronic Pa<strong>in</strong><br />

No biologic value 1-3<br />

Acts as warn<strong>in</strong>g system Detrimental effects 1-3<br />

<strong>in</strong>dicat<strong>in</strong>g tissue <strong>in</strong>jury 1 Persists beyond usual course<br />

Recent onset 2<br />

of acute illness or <strong>in</strong>jury<br />

F<strong>in</strong>ite duration (days<br />

(months to years) 1-3<br />

to weeks) 2<br />

Chronic pathologic process;<br />

Remits when underly<strong>in</strong>g<br />

may recur at <strong>in</strong>tervals 1-3<br />

pathology resolves 1<br />

1. Brookoff D. Hosp Pract. 2000;35:45-52,59. 2. Portenoy RK, Kanner RM, eds. Pa<strong>in</strong> Management: Theory and Practice.<br />

Philadelphia, PA: FA Davis Co; 1996:248-276. 3. Turk DC, Melzack R, eds. Handbook of Pa<strong>in</strong> Assessment. 2nd ed. New<br />

York, The Guilford Press; 2001:3-11.<br />

Pa<strong>in</strong> classification<br />

Diagnostic classification<br />

A. Nociceptive pa<strong>in</strong><br />

I. Somatic: well localized; e.g. sk<strong>in</strong>, bones<br />

II. Visceral: poorly localized; e.g. organs<br />

B. Neuropathic pa<strong>in</strong><br />

I. Central: Localized and diffused; burn<strong>in</strong>g, stabb<strong>in</strong>g pa<strong>in</strong><br />

e.g. CNS<br />

II. Peripheral: localized neuropathies<br />

Pa<strong>in</strong> Management Guidel<strong>in</strong>es<br />

World Health<br />

Organization’s<br />

Pa<strong>in</strong> Relief<br />

Ladder<br />

C. Idiopathic pa<strong>in</strong><br />

usually <strong>in</strong> head, shoulders, or pelvic areas<br />

Cancer Pa<strong>in</strong> Relief and Palliative Care. Geneva, Switzerland; World Health Organization; 1990.<br />

Therapeutic Strategies<br />

<strong>in</strong> Pa<strong>in</strong> Management<br />

Equianalgesic Dose Table<br />

• Lifestyle changes<br />

• Rehabilitative<br />

• Psychological<br />

• Complementary and <strong>in</strong>tegrative medic<strong>in</strong>e<br />

• Educational<br />

• Pharmacotherapy<br />

• Injection, surgical, neuromodulation<br />

• Googl<strong>in</strong>g “Equianalgesic Dose Table”<br />

yields 27,400 citations<br />

• Many different versions<br />

• Based on short-term trials of acute post-op<br />

pa<strong>in</strong> or low doses <strong>in</strong> cancer patients<br />

• Patient-specific variables<br />

• Unidirectional vs bidirectional<br />

equivalencies<br />

F<strong>in</strong>e PG, Portenoy RK. A Cl<strong>in</strong>ical Guide to Opioid Analgesia.<br />

M<strong>in</strong>neapolis, MN: McGraw-Hill; 2004.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!